Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BrainStorm Establishes Safety of Repeat Doses of NurOwn in Mice

Published: Friday, January 11, 2013
Last Updated: Friday, January 11, 2013
Bookmark and Share
Pre-clinical study conducted at GLP-compliant Harlan Laboratories.

BrainStorm Cell Therapeutics announced that it has successfully completed a 12-week repeat dose toxicity study with its NurOwn cells in mice. The company believes that the positive data from the study will support its efforts to obtain approval for a future repeat dose clinical study in ALS patients. The study was conducted at Harlan Israel’s laboratories, according to GLP (Good Laboratory Practice) standards of the FDA. The study protocol was approved by the Israeli Ministry of Health.

“We believe that repeat dosing is the key to the long-term clinical efficacy of NurOwn and we are anxious to begin testing in ALS patients. Our proprietary cryopreservation protocol will enable us to do so without having to perform repeat bone marrow aspirations for each dose,” commented Dr. Adrian Harel, BrainStorm’s CEO.

In the study, the animals received up to three intramuscular injections of NurOwn, produced from cryopreserved, or frozen, cells at concentrations 50–100 times the currently administered clinical trial dose. The treatment was well tolerated, and no adverse clinical effects were observed. Analyses included cytokine profile assays, clinical pathology, necropsy and macroscopic examination, as well as histopathological examinations.

BrainStorm is currently launching a Phase IIa combined treatment, dose-escalating trial of its NurOwn cell therapy candidate in ALS patients at the Hadassah Medical Center in Jerusalem. The company was recently fast-tracked by the Israeli Ministry of Health after reporting positive safety data for 12 patients in a Phase I/II trial.

BrainStorm is planning to expand its ALS clinical development to the United States in 2013, pending FDA approval. Towards that goal, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS clinical trials at these institutions.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First Patient Enrolled in BrainStorm's Phase II ALS Trial
Patient enrollment in Phase II trial at Massachusetts General Hospital in Boston.
Tuesday, June 10, 2014
BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
Mr. Natanson succeeds Dr. Adrian Harel, who will move into an executive scientific role in the company.
Tuesday, January 29, 2013
BrainStorm Announces Clinical Data for Safety and Supporting Efficacy of NurOwn™ Based on Initial Phase I/II Results
Data from patients in ALS Phase I/II human clinical trial treated with NurOwn™ technology do not show any side effects.
Wednesday, January 18, 2012
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
New funding includes a grant from the Israeli government’s Office of the Chief Scientist and private investment.
Monday, September 07, 2009
BrainStorm Cell Therapeutics’ Adult Stem Cell Approach More Relevant than Embryonic Stem Cell Therapies
The Company claims that its adult stem cell therapies provide a safer approach at treating neurodegenerative diseases than competitive therapies that rely on embryonic stem cells.
Thursday, November 29, 2007
BrainStorm Cell Therapeutics Initiates Stem Cell Safety Study in Primates for Parkinson’s Disease
The Company has initiated a safety trial using an animal model of Parkinson’s disease in primates utilizing its adult stem cell technology.
Thursday, February 15, 2007
BrainStorm Targets Treatment of Stroke with its Adult Stem Cell Technology
BrainStorm’s bone marrow stem cell technology can differentiate adult stem cells into astrocyte-like cells.
Friday, August 25, 2006
BrainStorm Advances International Patent Application for Stem Cell Procedure
The patent protects a procedure for inducing bone marrow stem cells to differentiate into astrocytes.
Wednesday, July 12, 2006
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!